Dr. Chong Xu focuses primarily on biopharmaceutical and medical technology sectors. He works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. At F-Prime, Chong has been involved in a number of company formations including as a founding investor of Skyline Therapeutics, K36 Therapeutics, and AlphaGen. Prior to joining F-Prime in 2015, Chong was a consultant in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a PhD in Cell Biology from University of Virginia and an MBA from Darden School of Business, University of Virginia.

.